Suicide Risk Not Up With New Rx of 5α-Reductase Inhibitor for BPH

Share this content:
Suicide Risk Not Up With New Rx of 5α-Reductase Inhibitor for BPH
Suicide Risk Not Up With New Rx of 5α-Reductase Inhibitor for BPH

MONDAY, March 27, 2017 (HealthDay News) -- For older men, initiation of a new prescription of a 5α-reductase inhibitor for the treatment of benign prostatic hyperplasia is not associated with increased risk of suicide, according to a study published online March 20 in JAMA Internal Medicine.

Blayne Welk, M.D., from Western University in London, Canada, and colleagues conducted a retrospective cohort study using linked administrative data for 93,197 men ages 66 years or older who initiated a new prescription for a 5α-reductase inhibitor during 2003 to 2013. Participants were propensity score-matched to an equal number of men not prescribed a 5α-reductase inhibitor.

The researchers observed no increased risk of suicide for men who used 5α-reductase inhibitors (hazard ratio [HR], 0.88; 95 percent confidence interval [CI], 0.53 to 1.45). During the initial 18 months after initiation of a 5α-reductase inhibitor, but not thereafter, the risk of self-harm was significantly increased (HR, 1.88; 95 percent CI, 1.34 to 2.64). During the initial 18 months after initiation of a 5α-reductase inhibitor, the risk of incident depression was elevated (HR, 1.94; 95 percent CI, 1.73 to 2.16), and the elevation continued, to a lesser extent, for the remainder of the follow-up period (HR, 1.22; 95 percent CI, 1.08 to 1.37). For these two outcomes, the absolute increases in the event rates were 17 and 237 per 100,000 patient-years, respectively.

"This is in keeping with post-marketing experience and patient concerns, and discontinuation of the medication in these circumstances may be appropriate," the authors write.

One author disclosed financial ties to Astellas.

Abstract/Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Actemra to Treat Giant Cell Arteritis

FDA Approves Actemra to Treat Giant Cell Arteritis

New indication provides the first FDA-approved therapy specific to this type of vasculitis

Trends in Teen Binge Drinking Still Raise Concerns

Trends in Teen Binge Drinking Still Raise Concerns

Even though frequent binge drinking among adolescents has dropped in past 25 years

ATS: First Abx Rx Doesn't Work for 25 of Pneumonia Cases

ATS: First Abx Rx Doesn't Work for ~25% ...

One in four adult patients do not respond to initial prescription of antibiotic treatment

is free, fast, and customized just for you!

Already a member?

Sign In Now »